| Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations F Karzai, D VanderWeele, RA Madan, H Owens, LM Cordes, A Hankin, ... Journal for immunotherapy of cancer 6, 1-12, 2018 | 242 | 2018 |
| Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors M Bilusic, CR Heery, JM Collins, RN Donahue, C Palena, RA Madan, ... Journal for immunotherapy of cancer 7, 1-8, 2019 | 191 | 2019 |
| A PDX/organoid biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening ML Beshiri, CM Tice, C Tran, HM Nguyen, AG Sowalsky, S Agarwal, ... Clinical Cancer Research 24 (17), 4332-4345, 2018 | 175 | 2018 |
| Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies J Strauss, ME Gatti-Mays, BC Cho, A Hill, S Salas, E McClay, JM Redman, ... Journal for immunotherapy of cancer 8 (2), 2020 | 89 | 2020 |
| A phase I study of TRC 105 anti‐endoglin (CD 105) antibody in metastatic castration‐resistant prostate cancer FH Karzai, AB Apolo, L Cao, RA Madan, DE Adelberg, H Parnes, ... BJU international 116 (4), 546-555, 2015 | 74 | 2015 |
| Low abundance of circulating tumor DNA in localized prostate cancer ST Hennigan, SY Trostel, NT Terrigino, OS Voznesensky, RJ Schaefer, ... JCO precision oncology 3, 2019 | 68 | 2019 |
| Accelerating precision medicine in metastatic prostate cancer J Mateo, R McKay, W Abida, R Aggarwal, J Alumkal, A Alva, F Feng, ... Nature cancer 1 (11), 1041-1053, 2020 | 56 | 2020 |
| Nascent prostate cancer heterogeneity drives evolution and resistance to intense hormonal therapy S Wilkinson, H Ye, F Karzai, SA Harmon, NT Terrigino, DJ VanderWeele, ... European urology 80 (6), 746-757, 2021 | 53 | 2021 |
| A phase II clinical trial of TRC105 (anti-endoglin antibody) in adults with advanced/metastatic urothelial carcinoma AB Apolo, FH Karzai, JB Trepel, S Alarcon, S Lee, MJ Lee, Y Tomita, ... Clinical genitourinary cancer 15 (1), 77-85, 2017 | 53 | 2017 |
| Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer HA Sater, JL Marté, RN Donahue, B Walter-Rodriguez, CR Heery, ... Journal for immunotherapy of cancer 8 (1), 2020 | 47 | 2020 |
| A phase I trial using a multitargeted recombinant adenovirus 5 (CEA/MUC1/Brachyury)‐based immunotherapy vaccine regimen in patients with advanced cancer ME Gatti‐Mays, JM Redman, RN Donahue, C Palena, RA Madan, ... The oncologist 25 (6), 479-e899, 2020 | 46 | 2020 |
| A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild‐Type, Advanced Triple‐Negative Breast Cancer ME Gatti‐Mays, FH Karzai, SN Soltani, A Zimmer, JE Green, MJ Lee, ... The Oncologist 25 (12), 1013-e1824, 2020 | 44 | 2020 |
| A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population. F Karzai, RA Madan, H Owens, A Couvillon, A Hankin, M Williams, ... Journal of Clinical Oncology 36 (6_suppl), 163-163, 2018 | 41 | 2018 |
| Avelumab in metastatic castration-resistant prostate cancer (mCRPC). F Fakhrejahani, RA Madan, WL Dahut, M Bilusic, F Karzai, LM Cordes, ... Journal of Clinical Oncology 35 (15_suppl), 5037-5037, 2017 | 36 | 2017 |
| Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC) M Bilusic, S McMahon, RA Madan, F Karzai, YT Tsai, RN Donahue, ... Journal for immunotherapy of cancer 9 (3), 2021 | 34 | 2021 |
| Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis SM Troutman, TM Sissung, CD Cropp, DJ Venzon, SD Spencer, ... The Oncologist 17 (3), 312-320, 2012 | 33 | 2012 |
| Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer RA Madan, FH Karzai, YM Ning, BA Adesunloye, X Huang, N Harold, ... BJU international 118 (4), 590-597, 2016 | 28 | 2016 |
| Sequential prostate magnetic resonance imaging in newly diagnosed high-risk prostate cancer treated with neoadjuvant enzalutamide is predictive of therapeutic response F Karzai, SM Walker, S Wilkinson, RA Madan, JH Shih, MJ Merino, ... Clinical Cancer Research 27 (2), 429-437, 2021 | 26 | 2021 |
| A case report of multiple primary prostate tumors with differential drug sensitivity S Wilkinson, SA Harmon, NT Terrigino, F Karzai, PA Pinto, RA Madan, ... Nature communications 11 (1), 837, 2020 | 26 | 2020 |
| Phase I trial of a modified vaccinia ankara priming vaccine followed by a fowlpox virus boosting vaccine modified to express brachyury and costimulatory molecules in advanced … JM Collins, RN Donahue, YT Tsai, M Manu, C Palena, ME Gatti‐Mays, ... The oncologist 25 (7), 560-e1006, 2020 | 23 | 2020 |
James L. GulleyNational Cancer InstituteVerified email at mail.nih.gov
